Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.

@article{Olejniczak2008AcquiredRT,
  title={Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.},
  author={Scott H Olejniczak and Francisco J Hernandez-Ilizaliturri and James Lindsey Clements and Myron S. Czuczman},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2008},
  volume={14 5},
  pages={1550-60}
}
PURPOSE Targeting malignant B cells using rituximab (anti-CD20) has improved the efficacy of chemotherapy regimens used to treat patients with non-Hodgkin's lymphoma. Despite the promising clinical results obtained using rituximab, many patients relapse with therapy-resistant disease following rituximab-based treatments. We have created a cell line model of rituximab resistance using three B-cell non-Hodgkin's lymphoma-derived cell lines (Raji, RL, and SUDHL-4). In an attempt to define… CONTINUE READING
40 Citations
39 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 40 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma

  • EspinaV Gulmann C, E Petricoin
  • Clin Cancer Res
  • 2005

death : critical control points

  • IS Goping, LavoieJN Gross A
  • Cell
  • 2004

Similar Papers

Loading similar papers…